These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 2260139)

  • 1. Effect of Bay U 3405, a new thromboxane antagonist, on collagen-induced thromboembolism in rabbits.
    Seuter F; Perzborn E; Fiedler VB
    Stroke; 1990 Dec; 21(12 Suppl):IV146-8. PubMed ID: 2260139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of Bay U 3405, a novel thromboxane A2/endoperoxide receptor antagonist.
    Perzborn E; Fiedler VB; Seuter F; Stasch JP; Weber H; Sander E; Böshagen H; Rosentreter U
    Stroke; 1990 Dec; 21(12 Suppl):IV143-5. PubMed ID: 2148034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of BAY U 3405, a new thromboxane antagonist, on sudden death in rabbits.
    Seuter F; Perzborn E; Fiedler VB; Rosentreter U; Böshagen H
    J Lipid Mediat; 1991; 3(3):283-8. PubMed ID: 1773029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of the protective action of Bay-u-3405, a new specific thromboxane receptor antagonist, in arachidonate-induced sudden death.
    Ma XL; Karasawa A; Lefer AM
    Methods Find Exp Clin Pharmacol; 1991 Mar; 13(2):105-10. PubMed ID: 1906568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of in vivo coronary artery thrombosis by the novel thromboxane antagonist (3R)-3-(4-fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9- carbazolepropanoic acid.
    Fiedler VB; Perzborn E; Seuter F; Rosentreter U; Böshagen H
    Arzneimittelforschung; 1989 Dec; 39(12):1527-30. PubMed ID: 2624600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of BAY U 3405, a new thromboxane antagonist, on arachidonic acid induced thromboembolism.
    Seuter F; Perzborn E; Fiedler VB
    Adv Prostaglandin Thromboxane Leukot Res; 1991; 21A():355-8. PubMed ID: 1825569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bay U 3405 inhibits cerebral vasospasm induced by authentic thromboxane A2.
    Braun M; Schrör K
    Stroke; 1990 Dec; 21(12 Suppl):IV152-4. PubMed ID: 2260141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of platelet aggregation in vitro and ex vivo by the new thromboxane antagonist (3R)-3-(4-fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9- carbazolepropanoic acid.
    Seuter F; Perzborn E; Rosentreter U; Böshagen H; Fiedler VB
    Arzneimittelforschung; 1989 Dec; 39(12):1525-7. PubMed ID: 2624599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and absolute configuration of the new thromboxane antagonist (3R)-3-(4-fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9-carbazolepropan oic acid and comparison with its enantiomer.
    Rosentreter U; Böshagen H; Seuter F; Perzborn E; Fiedler VB
    Arzneimittelforschung; 1989 Dec; 39(12):1519-21. PubMed ID: 2624597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the novel thromboxane antagonist Bay U 3405 on experimental coronary artery disease.
    Fiedler VB; Seuter F; Perzborn E
    Stroke; 1990 Dec; 21(12 Suppl):IV149-51. PubMed ID: 2260140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective effect of a novel thromboxane antagonist, BAY-U3405, on canine myocardial damage after coronary artery occlusion and reperfusion.
    Fiedler VB; Perzborn E; Seuter F
    Pharmacotherapy; 1991; 11(1):77-84. PubMed ID: 2020615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of an oral thromboxane TP receptor antagonist BAY u 3405, on prostaglandin D2- and histamine-induced bronchoconstriction in asthma, and relationship to plasma drug concentrations.
    Johnston SL; Bardin PG; Harrison J; Ritter W; Joubert JR; Holgate ST
    Br J Clin Pharmacol; 1992 Nov; 34(5):402-8. PubMed ID: 1467134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective effects of BAY U 3405, a thromboxane A2 receptor antagonist, in endotoxin shock.
    Altavilla D; Canale P; Squadrito F; Sardella A; Ammendolia L; Urna G; Ioculano M; Squadrito G; Caputi AP
    Pharmacol Res; 1994; 30(2):137-51. PubMed ID: 7816742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiaggregant and antivasospastic properties of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate.
    Lardy C; Rousselot C; Chavernac G; Depin JC; Guerrier D
    Arzneimittelforschung; 1994 Nov; 44(11):1196-202. PubMed ID: 7848331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Action of the novel selective thromboxane antagonist (3R)-3-(4-fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9-carbazolepropan oic acid on vascular smooth muscle preparations.
    Perzborn E; Seuter F; Fiedler VB; Rosentreter U; Böshagen H
    Arzneimittelforschung; 1989 Dec; 39(12):1522-5. PubMed ID: 2624598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparative study of the antithrombotic effect of aspirin and Bay U3405, antagonist of a thromboxane A2 receptor].
    Cissé-Thiam M; Drouet L
    Dakar Med; 1999; 44(1):25-7. PubMed ID: 10797981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of prostanoid-mediated platelet aggregation in vivo and in vitro by 3-hydroxymethyl-dibenzo(b,f)thiepin 5,5-dioxide (L-640,035).
    Chan CC; Nathaniel DJ; Yusko PJ; Hall RA; Ford-Hutchinson AW
    J Pharmacol Exp Ther; 1984 Apr; 229(1):276-82. PubMed ID: 6423813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of thromboxane A2 in myocardial ischemia and circulatory shock.
    Lefer AM
    Adv Prostaglandin Thromboxane Leukot Res; 1989; 19():321-6. PubMed ID: 2526491
    [No Abstract]   [Full Text] [Related]  

  • 19. Protamine-heparin-induced pulmonary hypertension in pigs: effects of treatment with a thromboxane receptor antagonist on hemodynamics and coagulation.
    Nuttall GA; Murray MJ; Bowie EJ
    Anesthesiology; 1991 Jan; 74(1):138-45. PubMed ID: 1824742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and metabolism of the new thromboxane A2 receptor antagonist ramatroban in animals. 2nd communication: distribution to organs and tissues in male, female and pregnant rats, and characteristics of protein binding in plasma.
    Steinke W; Ahr HJ; Hirayama M
    Arzneimittelforschung; 1997 Aug; 47(8):939-48. PubMed ID: 9296280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.